Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibulizumab in Primary Sjogren's Syndrome
NCT04563195Phase 3Withdrawn
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tibulizumab. Planned start Feb 2022; status: withdrawn.
02
Drugs
tibulizumab
Beyond the preview
Go deeper on NCT04563195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563195.